© 2018  Cord Blood Association
The presentations at the 2018 Cord Blood Connect international congress are the property of the Cord Blood Association. They are posted for personal reference by the website visitor. Download, reproduction or any other use of the audio, video or visuals of these presentations is prohibited without the written permission of the Cord Blood Association.
Friday, September 14
Welcome and Congress Overview
Joanne Kurtzberg, Colleen Delaney and Sharon Miller
Keynote Lecture: Success and Challenges of Cord Blood Transplant
Eliane Gluckman  
Saturday, September 15
FDA’s Approach to the Regulation  of Regenerative Medicine Products
Peter Marks
Cord Blood-Derived Exosome-Based Therapies
Elizabeth Shpall
Overcoming Collection Obstacles: Public and Family Banking Perspectives
Ann Kaestner and Kate Girard
Placental MSC To Reverse Aging
Robert Hariri
Treatment of Childhood Cerebral Palsy with Cord Blood
Jessica Sun
Specification Requirements  for Releasing Cellular Therapeutic Products for Clinical Application
Ngaire Elwood
Original Pioneers
Arleen Auerbach, Hal Broxmeyer, Matthew Farrow, Eliane Gluckman, Joanne Kurtzberg and John Wagner
21st Century Cures Act Impact on Cord Blood and Cord Tissues
Janet Marchibroda and Marc Scheineson
Manufacturing MSC from Marrow: Role of Culture Rescue
Jan Nolta
Continued Funding of Public Cord Blood in the United Kingdom
Charlie Craddock
Optimizing Cord Blood Collection with the Resurgence of Delayed Cord Clamping
Heidi Elmoazzen
Collecting High Volume  Units – Tricks and Tools
Deborah Wood
New Standards and Tools for Cord Blood and Perinatal Tissues under the EU-ATMP Regulation
Gesine Kögler
Current FDA Guidance Relative to Homologous Use in HPC and Regenerative Therapies
Sharon Miller
Public Cord Blood as a Desirable Graft Source
Karen Ballen
Overview of Cord Blood-Derived Immunotherapies
Vanderson Rocha
T-Regs
Claudio Brunstein
Bone Marrow MSC To Treat Adult Frailty
Aisha Khan
Biopreservation Best Practices for Cells and Tissues
Aby J. Mathew
Excellent Outcomes after Umbilical Cord Blood Transplantation Using a Centralized Cord Blood Registry
Karen Ballen
Noninvasive, Fast and Cost-Effective Qualification of Blood Collection Bags
Francisco (Paco) Robles
Toward a Sustainable Cord Blood Supply in the United States
Kandice Kapinos
Sunday, September 16
Influence of Microbiome on Hematopoietic Cell Therapy Outcomes
‍Jonathan Peled
Fucosylation  
Elizabeth Shpall
The Use of Umbilical Cord Tissue for Isolating CL-MSC in Treatment for Diabetic Foot Ulcers
J. Robert Chang
Next Generation Conditioning Regimens: Reduced Toxicity without Increased Risk of Relapse
‍Juliet Barker
Homing and Ex-Vivo Expansion  
Hal Broxmeyer
Pediatric AML Donor Comparison or Immune Reconstitution
Jaap-Jan Boelens
Outcome Data in the Research Environment  
Stephen Spellman
Panel Discussion on Homing and Ex-Vivo Expansion.
‍Jaap-Jan Boelens, Vanderson Rocha and John Wagner
Considering the “What Ifs”  
Jaap-Jan Boelens, Colleen Delaney, Eliane Gluckman, Joanne Kurtzberg, Sharon Miller, C. Randall Mills and Vanderson Rocha
The following presentations are not available, by agreement with the authors:
Evolving Ethical Considerations in Regenerative Medicine:  Jeremy Sugarman
‍
Manufacturing MSC from Allogeneic Cord Tissue: Joanne Kurtzberg
‍
Characterization and Variability of MSCs from Multiple Tissue Sources – A Consortium Approach: Krishnendu Roy
‍
‍Cord Blood-Derived Virus-Specific T-Cells: Catherine Bollard
‍
Treatment  of Childhood Autism with Cord Tissue MSCs: Geraldine Dawson
‍
Microbial Contamination in Umbilical Cord Blood: A Comparison Before and After Cryopreservation: Mingming Li
‍
Cord Blood-Derived NK-CAR Cells for Treatment of Cancer: Katy Rezvani
‍
Post-HCT Viral Infections: Prophylaxis in Cord Blood Transplant Patients:
Michael Boeckh
‍
NICORD Ex-Vivo Expansion:
‍Mitchell Horwitz
‍
Magenta: Michael Cooke
‍
Nohla: Colleen Delaney
‍
ExcellThera: Sandra Cohen
‍
Feasibility and Reimbursement: FDA Approved Therapy Lessons: Stephanie Farnia
Evolving Ethical Considerations in Regenerative Medicine:  Jeremy Sugarman
Manufacturing MSC from Allogeneic Cord Tissue: Joanne Kurtzberg
Characterization and Variability of MSCs from Multiple Tissue Sources – A Consortium Approach: Krishnendu Roy
Cord Blood-Derived Virus-Specific T-Cells: Catherine Bollard
Treatment of Childhood Autism with Cord Tissue MSCs: Geraldine Dawson
Microbial Contamination in Umbilical Cord Blood: A Comparison Before and After Cryopreservation: Mingming Li
Cord Blood-Derived NK-CAR Cells for Treatment of Cancer: Katy Rezvani
Post-HCT Viral Infections: Prophylaxis in Cord Blood Transplant Patients: Michael Boeckh
NICORD Ex-Vivo Expansion: Mitchell Horwitz
Magenta: Michael Cooke
Nohla: Colleen Delaney
ExcellThera: Sandra Cohen
Feasibility and Reimbursement: FDA Approved Therapy Lessons: Stephanie Farnia